At Aquila, we provide tailored assays to study the effects of your drug candidate on NK cells and the wider immune response.
Because of their ability to kill tumour cells, NK cells are an attractive target for cancer immunotherapies especially therapeutic monoclonal antibodies, which act through antibody-mediated cellular cytotoxicity (ADCC).
Whether you’re investigating target antigen expression on tumour cells/cell lines or by immune suppressive cells such as regulatory T cells, M2 macrophages or myeloid-derived suppressor cells (MDSC) to drive an ADCC reaction, or evaluating NK cell cytotoxicity function, we can design a custom program around NK cells that specifically meets your research needs. Our scientific team can guide you in answering research questions to understand your molecule’s MOA, efficacy or aid in lead optimisation.
We also offer custom and standard assay readouts such as cytokine expression by ELISA or multiplex, proliferation and cell surface markers using FACS, and live cell imaging using the IncuCyte Live-Cell Analysis System.
To learn more about some of our NK cell assays, click here:
Or please get in touch to learn more about our NK cell related services.